Last updated on December 2018

The ProVent Study is designed to look at subjects who receive sipuleucel-T compared to control subjects followed on active surveillance as standard of care.


Brief description of study

This study is being conducted to learn more about a prostate cancer treatment called sipuleucel-T, a cell-based immunotherapy, in early stage prostate cancer that has not spread outside of the prostate.  Sipuleucel-T has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castrate resistant prostate cancer (prostate cancer that has spread outside of the prostate and is resistant to medical or surgical treatments that lower testosterone).

 

Detailed Study Description

Patients who wish to enroll in a research study should discuss the possibilities with their urologist. The TUCC Clinical Research Department staff remains in constant communication with patients throughout their enrollment in clinical trials. These patients receive all study related medication and procedures at no cost. Participation is voluntary and patients can choose to withdraw from clinical trials at any time.

 

Clinical Study Identifier: TX217802

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.